Patents Assigned to Genentech
  • ANTIBODY PURIFICATION BY CATION EXCHANGE CHROMATOGRAPHY
    Publication number: 20180118781
    Abstract: A method for purifying an antibody by cation exchange chromatography is described in which a high pH wash step is used to remove of contaminants prior to eluting the desired antibody using an elation buffer with increased conductivity.
    Type: Application
    Filed: December 21, 2017
    Publication date: May 3, 2018
    Applicant: Genentech, Inc.
    Inventors: Benedicte Andree Lebreton, Deborah Ann O'Connor, Aurelia Safta, Mandakini Sharma
  • BIHETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20180117044
    Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 3, 2018
    Applicant: Genentech, Inc.
    Inventors: Anthony O. Estrada, Alan G. Olivero, Snahel Patel, Michael Siu, Joseph Lyssikatos
  • POLYNUCLEOTIDES ENCODING ANTI-NOTCH1 NRR ANTIBODY POLYPEPTIDES
    Publication number: 20180112005
    Abstract: The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: October 2, 2017
    Publication date: April 26, 2018
    Applicant: Genentech, Inc.
    Inventors: Christian W. Siebel, Yan Wu
  • Azaindazole compounds as inhibitors of T790M containing EGFR mutants
    Patent number: 9951064
    Abstract: This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: April 24, 2018
    Assignee: GENENTECH, INC.
    Inventors: Marian C. Bryan, Bryan Chan, Francois Diederich, Jennafer Dotson, Emily Hanan, Timothy Heffron, Michael Lainchbury, Robert Heald, Eileen M. Seward
  • Anti-CD33 antibodies and immunoconjugates
    Patent number: 9951133
    Abstract: The invention provides anti-CD33 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: April 24, 2018
    Assignee: GENENTECH, INC.
    Inventors: Shang-Fan Yu, Wei-Ching Liang, Yan Wu, Steven Leong, Andrew Polson
  • ARYL SULTAM DERIVATIVES AS RORc MODULATORS
    Publication number: 20180105516
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X1, X2, X3, X4, Y, Z, A, Het, R1, R2, R3, R4, R5 R6, R7, R8, R9, R10, R11, R12 and R13 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.
    Type: Application
    Filed: December 19, 2017
    Publication date: April 19, 2018
    Applicant: Genentech, Inc.
    Inventors: Benjamin FAUBER, Emanuela GANCIA, Tammy LADDUWAHETTY, David VESEY, Paul WINSHIP, Olivier RENE
  • ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR
    Publication number: 20180106809
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.
    Type: Application
    Filed: December 21, 2017
    Publication date: April 19, 2018
    Applicant: Genentech, Inc.
    Inventors: Mark S. Dennis, Bonnee Rubinfeld, Paul Polakis, Aya Jakobovits
  • THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20180105504
    Abstract: The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1-Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: October 31, 2017
    Publication date: April 19, 2018
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Daniel SUTHERLIN, Steven MCKERRALL, Michael Scott WILSON, Kwong Wah LAI, Philippe BERGERON, Birong ZHANG
  • Pharmaceutical compounds
    Patent number: 9943519
    Abstract: Compounds of Formulae Ia, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: April 17, 2018
    Assignees: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Adrian Folkes, Stephen Shuttleworth, Irina Chuckowree, Sally Oxenford, Nan Chi Wan, Georgette Castanedo, Richard Goldsmith, Janet Gunzer-Toste, Tim Heffron, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Bing-Yan Zhu
  • Compositions and methods for detecting and quantifying host cells protein in cell lines and recombinant polypeptide products
    Patent number: 9945858
    Abstract: Monoclonal and polyclonal antibodies that bind hamster phospholipase B-like 2 are provided. Also provided are methods for detecting and quantifying hamster phospholipase B-like 2, for example, in recombinant polypeptide preparations, as well as kits for carrying out such methods. Methods of screening or selecting host cell lines or recombinant polypeptide-expressing cell lines that express low levels of hamster phospholipase B-like 2 are also provided.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: April 17, 2018
    Assignee: Genentech, Inc.
    Inventors: Feny Gunawan, Yi-Chun Hsiao, Denise C. Krawitz, Margaret S. Lin, Martin Vanderlaan, Rajesh Vij, Inn H. Yuk, Judith Zhu-Shimoni
  • FGFR1 AGONISTS AND METHODS OF USE
    Publication number: 20180100018
    Abstract: The invention provides nucleic acid molecules encoding anti-fibroblast growth factor receptor-1 (FGFR1) antibodies and vectors and host cells comprising the nucleic acid molecules.
    Type: Application
    Filed: November 10, 2017
    Publication date: April 12, 2018
    Applicant: Genentech, Inc.
    Inventors: Junichiro Sonoda, Yan WU
  • Modulation of axon degeneration
    Patent number: 9937224
    Abstract: The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: April 10, 2018
    Assignee: Genentech, Inc.
    Inventors: Ryan J. Watts, Mark Chen, Joseph Wesley Lewcock, Christine Pozniak, Arundhati Sengupta-Ghosh
  • ANTI-HER2 ANTIBODIES AND METHODS OF USE
    Publication number: 20180094056
    Abstract: The invention provides anti-HER2 antibodies, including anti-HER2 antibodies of improved stability or affinity, and methods of using the same.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 5, 2018
    Applicant: Genentech, Inc.
    Inventors: Mary Mathieu, Mark Dennis
  • Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
    Patent number: 9931323
    Abstract: Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: April 3, 2018
    Assignee: Genentech, Inc.
    Inventors: Jason Burch, Minghua Sun, Xiaojing Wang, Wesley Blackaby, Alastair James Hodges, Andrew Sharpe
  • INTEGRIN BETA7 ANTAGONISTS AND METHODS OF TREATING CROHN'S DISEASE
    Publication number: 20180086833
    Abstract: Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including Crohn's disease are provided. Also provided are methods of administering and dosing integrin beta7 antagonists, such as anti-integrin beta7 antibodies. In addition, methods of administrating and dosing such integrin beta7 antagonists to induce remission or to induce and maintain remission of Crohn's disease are provided.
    Type: Application
    Filed: August 21, 2017
    Publication date: March 29, 2018
    Applicant: Genentech, Inc.
    Inventors: Azra Hassanali, Romeo Maciuca, Meina Tao Tang, Swati Tole, Xiaohui Wei
  • PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS
    Publication number: 20180086722
    Abstract: The present invention relates to a process for the preparation of a compound of formula (I) wherein R1 is as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds.
    Type: Application
    Filed: November 30, 2017
    Publication date: March 29, 2018
    Applicant: GENENTECH, INC.
    Inventors: Hans Iding, Reinhard Reents, Michelangelo Scalone, Francis Gosselin
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20180086720
    Abstract: The present invention relates to compounds of formula (I): and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.
    Type: Application
    Filed: August 24, 2017
    Publication date: March 29, 2018
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Terry Crawford, Martin Duplessis, Andrew Charles Good, Yves LeBlanc, Steven R. Magnuson, Christopher G. Nasveschuk, Anthony F. Romero, Yong Tang, Alexander M. Taylor
  • ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES
    Publication number: 20180085470
    Abstract: The invention provides anti-wall teichoic acid antibodies, antibiotic-linker intermediates, and antibody-antibiotic conjugate compound, and methods of making and using the same.
    Type: Application
    Filed: December 7, 2017
    Publication date: March 29, 2018
    Applicant: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Composition and methods for the diagnosis of immune related diseases involving the PRO52254 polypeptide
    Patent number: RE46805
    Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases involving detection of the PRO52254 polypeptide.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: April 24, 2018
    Assignee: Genentech, Inc.
    Inventors: Daryl T. Baldwin, Sarah C. Bodary-Winter, Andrew C. Chan, Hilary Clark, Janet K. Jackman, William I. Wood
  • Composition and methods for the diagnosis of immune related diseases involving the PRO52254 polypeptide
    Patent number: RE46816
    Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases involving detection of the PRO52254 polypeptide.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: May 1, 2018
    Assignee: Genentech, Inc.
    Inventors: Daryl T. Baldwin, Sarah C. Bodary-Winter, Andrew C. Chan, Hilary Clark, Janet K. Jackman, William I. Wood